Information on the target
LEO III Fund has entered into a definitive agreement to acquire JPT Peptide Technologies GmbH from BioNTech Diagnostics GmbH. Established in 2004 as a spin-off from Jerini AG, JPT has emerged as a prominent provider of peptide-based research and development solutions on an international scale. Headquartered in Berlin, the company caters to a diverse clientele of over 20,000 customers across more than 100 countries, spanning sectors such as biopharma, cell and gene therapy, vaccine development, immunology, proteomics, and academic research.
With a workforce of approximately 130 employees, JPT has maintained ISO 9001 certification since its inception, underscoring its commitment to quality and excellence. As a standalone entity under the LEO III Fund, JPT is poised to enhance its technology platform, accelerate its international expansion in Europe and North America, and diversify its portfolio of peptide solutions.
Industry overview in the target’s specific country
The Biotechnology & Medical Research (NEC) industry in Germany is characterized by its robust innovation ecosystem, supported by a strong network of research institutions, universities, and industry players. Germany is recognized as one of the leading countries in Europe for biotechnology, with a significant number of biotech companies engaged in research and development activities. The country benefits from a well-established regulatory framework that fosters innovation while ensuring safety and efficacy in biopharmaceutical products.
In recent years, Germany has witnessed a surge in investment in biotechnology, driven by advancements in personalized medicine, gene therapy, and immunotherapy. The government has implemented various initiatives to promote research and development, including funding programs and tax incentives aimed at stimulating growth within the sector. This supportive environment has attracted both domestic and international investors, further enhancing the country's position as a hub for biotech innovation.
Moreover, the COVID-19 pandemic has accelerated the demand for biopharmaceutical solutions, leading to increased collaboration between biotech firms and academic institutions. This trend is expected to continue, as the industry adapts to emerging challenges and opportunities in healthcare. The presence of leading pharmaceutical companies and research organizations in Germany also contributes to a vibrant ecosystem that encourages knowledge transfer and collaboration.
As a result, the Biotechnology & Medical Research (NEC) industry in Germany is well-positioned for sustained growth, with a strong pipeline of innovative therapies and solutions that address crit…